Key result
Apelin-13 plus testosterone increases cell viability selectively in androgen receptor-positive prostate cancer cells.
Why the study?
Obesity-related apelin secretion may have significant effects on prostate cancer, but its impact on different prostate cancer cell lines is not fully understood.
Apelin-13 and testosterone increase cell viability in androgen receptor-positive prostate cancer cells (LNCaP) but not in androgen receptor-negative cells (DU-145).
Apelin-APJ signaling may link obesity to prostate cancer; leaves open whether it merits targeted investigation.
Prostate cancer is one of the most prevalent type of cancer in men. The exact solution for the treatment of different types of cancers has not been fully elucideted. Apelin secreted from adipose tissue reveals its effects by binding to APJ receptor. Obesity develops together with increased adipose tissue, and the increase of obesity related-apelin secretion is known. Obesity is a risk factor in the development of cancer, and considering both apelin and its receptor widely localized in the tissues of testis and prostate and apelin may have significant effects on prostate cancer. In the present study, 0.1, 1 and 10 nM concentrations of apelin-13 and three different testosterone concentrations (1, 10 and 100 nM) were separately aplied to human prostate cancer cells with LNCaP (androgen receptor positive) and DU-145 (androgen receptor negative). Then 1, 10 and 100 nM concentrations of testosterone hormone and 10 nM dose of apelin-13 incubated for 24 h in the prostate cancer cells were administrated and were allowed to incubate for 24 h. Effects of apelin-13 and testosterone on prostate cancer cells were determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. At the end of the experiment, DU-145 did not affected cell viability while the treatment with apelin -13 and testosterone increased the viability of LNCaP cells (p [Med-Science 2014; 3(3.000): 1427-41]
No takes yet. Share an insight, caveat, or question.
Tekin et al. (2014) studied Prostate cancer. Apelin-13 and testosterone was evaluated on Cell viability (MTT assay). Treatment with apelin-13 and testosterone increased the viability of androgen receptor-positive LNCaP cells but did not affect androgen receptor-negative DU-145 cells.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: